Cargando…

Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment

Intensive chemotherapeutic protocols and allogeneic stem cell transplantation continue to represent the mainstay of acute myeloid leukemia (AML) treatment. Although this approach leads to remissions in the majority of patients, long-term disease control remains unsatisfactory as mirrored by overall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gbolahan, Olumide Babajide, Zeidan, Amer M., Stahl, Maximilian, Abu Zaid, Mohammad, Farag, Sherif, Paczesny, Sophie, Konig, Heiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578050/ https://www.ncbi.nlm.nih.gov/pubmed/28758974 http://dx.doi.org/10.3390/ijms18081660

Ejemplares similares

Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2020)

What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach
por: Awada, Hussein, et al.
Publicado: (2023)

TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment
por: Depreter, Barbara, et al.
Publicado: (2020)

Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities
por: Stahl, Maximilian, et al.
Publicado: (2016)

Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

P477: COMBINATION OF DIFFERENT IMMUNOTHERAPEUTIC DRUGS ENHANCES SPECIFIC T CELL IMMUNE RESPONSES AGAINST LEUKEMIC CELLS AND LEUKEMIC PROGENITOR/STEM CELLS IN ACUTE MYELOID LEUKEMIA
por: Greiner, Jochen, et al.
Publicado: (2023)

The Yin-Yang of myeloid cells in the leukemic microenvironment: Immunological role and clinical implications
por: Magalhães-Gama, Fábio, et al.
Publicado: (2022)

Mapping and targeting of the leukemic microenvironment
por: Witkowski, Matthew T., et al.
Publicado: (2019)

Are We Moving the Needle for Patients with TP53-Mutated Acute Myeloid Leukemia?
por: Shallis, Rory M., et al.
Publicado: (2022)

Targeting the leukemic bone marrow microenvironment
por: von der Heide, Eva Kristin, et al.
Publicado: (2017)

Transmissible ER stress shapes the leukemic microenvironment
por: Butler, John T., et al.
Publicado: (2019)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021)

Radiotherapy remodels the tumor microenvironment for enhancing immunotherapeutic sensitivity
por: Liu, Senbo, et al.
Publicado: (2023)

CD34(+)CD38(−)CD123(+) Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents
por: Vergez, François, et al.
Publicado: (2020)

Circular RNAs Activity in the Leukemic Bone Marrow Microenvironment
por: Liccardo, Francesca, et al.
Publicado: (2022)

Pro-Apoptotic and Immunotherapeutic Effects of Carbon Nanotubes Functionalized with Recombinant Human Surfactant Protein D on Leukemic Cells
por: Khan, Haseeb A., et al.
Publicado: (2021)

Immunotherapeutic Implications of Toll-like Receptors Activation in Tumor Microenvironment
por: Zheng, Run, et al.
Publicado: (2022)

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Abaza, Yasmin, et al.
Publicado: (2022)

Challenges and Opportunities for Immunotherapeutic Intervention against Myeloid Immunosuppression in Glioblastoma
por: Exley, Mark A., et al.
Publicado: (2022)

P745: MULTI-CENTER PHASE IB TRIAL OF THE HISTONE DEACTYLASE INHIBITOR ENTINOSTAT + PEMBROLIZUMAB IN MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA REFRACTORY TO HYPOMETHYLATING AGENTS
por: Bewersdorf, Jan, et al.
Publicado: (2023)

Multi-spectral immunofluorescence evaluation of the myeloid, T cell, and natural killer cell tumor immune microenvironment in chordoma may guide immunotherapeutic strategies
por: Lopez, Diana C., et al.
Publicado: (2022)

Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies
por: Pombo Antunes, Ana Rita, et al.
Publicado: (2020)

CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
por: Seyfrid, Mathieu, et al.
Publicado: (2022)

Immune Microenvironment and Immunotherapeutic Management in Virus-Associated Digestive System Tumors
por: Sarantis, Panagiotis, et al.
Publicado: (2022)

The tumor microenvironment in gastrointestinal adenocarcinomas revealed a prognostic and immunotherapeutic biomarker
por: Zhang, Yong, et al.
Publicado: (2022)

Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia
por: Uy, Natalie, et al.
Publicado: (2018)

Myeloid progenitor cluster formation drives emergency and leukemic myelopoiesis
por: Hérault, Aurélie, et al.
Publicado: (2017)

Leukemic stem cells and therapy resistance in acute myeloid leukemia
por: Stelmach, Patrick, et al.
Publicado: (2023)

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
por: Xu, Qing-Yu, et al.
Publicado: (2020)

Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies
por: Pietsch, E C, et al.
Publicado: (2017)

Hexokinase II inhibition by 3-bromopyruvate sensitizes myeloid leukemic cells K-562 to anti-leukemic drug, daunorubicin
por: Rai, Yogesh, et al.
Publicado: (2019)

Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

A transient receptor potential channel-related model based on machine learning for evaluating tumor microenvironment and immunotherapeutic strategies in acute myeloid leukemia
por: Hua, Jingsheng, et al.
Publicado: (2022)

The Bone Marrow Microenvironment as Niche Retreats for Hematopoietic and Leukemic Stem Cells
por: Nwajei, Felix, et al.
Publicado: (2013)

Recreating the Bone Marrow Microenvironment to Model Leukemic Stem Cell Quiescence
por: O’Reilly, Eimear, et al.
Publicado: (2021)

COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and Immunotherapeutics)
por: Chary, Michael, et al.
Publicado: (2023)

Acute Myeloid Leukemia Leading to Central Diabetes Insipidus
por: Wojeck, Brian, et al.
Publicado: (2021)

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Wong, Kah Keng, et al.
Publicado: (2021)

Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
por: Sorrentino, Vincent G., et al.
Publicado: (2021)

The Immuno-Oncology and Genomic Aspects of DNA-Hypomethylating Therapeutics in Acute Myeloid Leukemia
por: Urabe, Akiko, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nop9j0o0rp38gn1b7m426ketfq